2025年以来,大批国产1类创新药迎来关键进展,其中不少产品被拟纳入突破性治疗品种,将为各类严重疾病患者带来效果或安全性更好的潜在治疗选择。以恒瑞医药为例,12月16日,其公告自主研发的注射用SHR-A1904拟纳入突破性治疗品种公示名单。据悉,这款靶向Claudin18.2的抗体偶联药物(ADC)在治疗晚期胃癌或胃食管结合部腺癌方面展现出巨大潜力。研究结果显示,在95名经过多线治疗的晚期胃/胃...
Source Link2025年以来,大批国产1类创新药迎来关键进展,其中不少产品被拟纳入突破性治疗品种,将为各类严重疾病患者带来效果或安全性更好的潜在治疗选择。以恒瑞医药为例,12月16日,其公告自主研发的注射用SHR-A1904拟纳入突破性治疗品种公示名单。据悉,这款靶向Claudin18.2的抗体偶联药物(ADC)在治疗晚期胃癌或胃食管结合部腺癌方面展现出巨大潜力。研究结果显示,在95名经过多线治疗的晚期胃/胃...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.